Better Coronavirus Stock: Quidel or Guardant Health? Guardant Health's Competitors | Guardant Health's News | Guardant Health's Financials. Advanced Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. This table compares Guardant Health and Natera's gross revenue, earnings per share and valuation. Precision oncology company Guardant Health, buoyed by its Guardant360 assay for matching cancer patients with … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Guardant Health has acquired the companies: Bellwether Bio, Inc. MarketScreener. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Comparatively, 3.1% of CareDx shares are held by company insiders. Companies like Guardant Health. Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. Let's conquer your financial goals together...faster. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Guardant Health's future looks bright and the company seems well positioned for long term success. Guardant Health has higher earnings, but lower revenue than Natera. Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. Learn more. Quest Diagnostics has a consensus price target of $126.6471, suggesting a potential upside of 1.97%. • List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Which of these healthcare stocks is a better buy for the long run? Comparatively, 94.1% of Invitae shares are held by institutional investors. This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Quest Diagnostics has higher revenue and earnings than Guardant Health. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. 76.2% of Guardant Health shares are held by institutional investors. It posted non-GAAP earnings per share (EPS) of $1.64 beating the consensus estimates by $0.38. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. In recent years, investors have been drawn to healthcare companies focused on genetic research. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. Guardant Health, Inc. was incorporated in 2011 and is … 76.2% of Guardant Health shares are owned by institutional investors. This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . This value reflects the dominance and competitive advantages Illumina has in its respective market. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. Get short term trading ideas from the MarketBeat Idea Engine. There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. In some cases apparently high growth rates may be caused by data that weren't available in previous years. 9.9% of Guardant Health shares are held by company insiders. Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Stock Advisor launched in February of 2002. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Start Your Risk-Free Trial Subscription Here, 3 Music Industry Stocks to Watch for 2021, Just Buy It: Nike Stock has the Legs to Remain a Long-Term Winner, Follow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase, Here’s Where to Ring the Register on Rite Aid (NYSE: RAD) Stock, Analysts Warm Up To Hotel Stocks, So Should You. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. Soon, it could detect cancer earlier than ever before. Comparatively, 84.1% of Natera shares are held by institutional investors. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. Do Not Sell My Information. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. Identify stocks that meet your criteria using seven unique stock screeners. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Want to see which stocks are moving? CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. Data Sources: Yahoo Finance, Illumina, Guardant Health. Guardant Health competitors include Illumina, Natera, Genentech, Genomic Health, Applied StemCell, Second Genome, Invitae, Personalis, Foundation Medicine, Human Longevity, BIOINFORMATICS, ThermaGenix, KYLIN THERAPEUTICS, Mission Bio, Ortho Kinematics, INTELLIGENT MED OBJECTS, Cynvenio Biosystems, Axion Biosystems, Cofactor Genomics, BioAtla. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. Data Sources: Yahoo Finance, Illumina, Guardant Health. Laboratory Co. of America has a consensus price target of $225.1875, suggesting a potential upside of 9.58%. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Now FDA Approved. Follow a manual added link. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). 9.9% of Guardant Health shares are held by company insiders. These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. December 8, 2020. Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Jackpot: Drills are Running Hot like Lava for this Company´s South American Super Project, These unique rock formations now host some of the highest-grade gold mineralization on the planet. 9.9% of Guardant Health shares are held by company insiders. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Should you be buying GH stock or one of its competitors? Germany's Qiagen sees solid growth in … Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Illumina vs. Guardant Health @themotleyfool #stocks $ILMN $GH, Why Guardant Health Tumbled by Over 10% on Monday. Learn about financial terms, types of investments, trading strategies and more. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Veracyte. Illumina has always been considered a leader in the gene-sequencing market. Guardant Health has higher earnings, but lower revenue than Invitae. Guardant Health beats Invitae on 10 of the 14 factors compared between the two stocks. This table compares Guardant Health and Veracyte's net margins, return on equity and return on assets. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Learn everything you need to know about successful options trading with this three-part video course. Both products are in the process of development as a companion diagnostic (CDx) for use in non-small cell lung cancer (NSCLC). 9.9% of Guardant Health shares are held by company insiders. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. See what's happening in the market right now with MarketBeat's real-time news feed. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. 9.9% of Guardant Health shares are owned by insiders. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. 76.2% of Guardant Health shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Some of the competitors of Guardant Health are Genentech, Illumina, and Genomic Health. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. Get daily stock ideas top-performing Wall Street analysts. Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. Where is Guardant Health headquarters? Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. Comparatively, Veracyte has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? See you at the top! This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. Companies may grow organically or through acquisition. Comparatively, 2.9% of Invitae shares are held by company insiders. 76.2% of Guardant Health shares are held by institutional investors. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. Fundamental company data provided by Morningstar and Zacks Investment Research. There are two Lunar programs: Lunar-1 and Lunar-2. GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. Comparatively, 9.3% of Natera shares are held by company insiders. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. CareDx has lower revenue, but higher earnings than Guardant Health. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Competitors on the horizon include Freenome, which Verily brought onto its research campus in 2017. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Together they have raised over 2.9B between their estimated 271.6K employees. Comparatively, 8.3% of Veracyte shares are held by company insiders. Guardant Health (NASDAQ:GH) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. Laboratory Co. of America has higher revenue and earnings than Guardant Health. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. All rights reserved. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and early detection. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. A simple blood draw helps cancer patients get the right drug. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. "Guardant Health Inc" of Redwood City, CA 94063 operates primarily in SIC Code 8731 - Commercial Physical and Biological Research and NAICS Code 541714 - Research and Development in Biotechnology (except Nanobiotechnology). Both companies have plenty of cash to operate, but Illumina commands a market valuation of $54.2 billion, nearly seven times the $7.9 billion market cap of Guardant Health. Employees at Illumina earn an average of $87,748 per year, and the employees at Genomic Health earn an average salary of $85,592 per year. Analyzing Guardant Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. Export data to Excel for your own analysis. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Please log in to your account or sign up in order to add this asset to your watchlist. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. How Guardant Health is Supporting Cancer Care During the Pandemic. Receive a free world-class investing education from MarketBeat. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. © American Consumer News, LLC dba MarketBeat® 2010-2020. 76.2% of Guardant Health shares are held by institutional investors. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. It maintains over 70% of the sequencing market and specializes in providing instruments and tools to a variety of customers such as academic institutions and government, pharmaceutical, and biotechnology companies across the world. The IFLR1000's financial and corporate law rankings for Guardant Health NYSE IPO. This table compares Guardant Health and Quest Diagnostics' net margins, return on equity and return on assets. View which stocks are hot on social media with MarketBeat's trending stocks report. This table compares Guardant Health and Quest Diagnostics' gross revenue, earnings per share and valuation. Looking for new stock ideas? Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Learn more. Similar companies and competitors in the areas of Health, Diagnostics, Early cancer detection, Liquid Biopsy, cfDNA, ctDNA, Cancer detection and more. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health beats Veracyte on 8 of the 14 factors compared between the two stocks. Veracyte has lower revenue, but higher earnings than Guardant Health. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Should You Buy the Peloton (NASDAQ: PTON) Rally? Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. To see all exchange delays and terms of use please see disclaimer. NEW YORK – A federal court has determined that Guardant Health CEO and Cofounder Helmy Eltoukhy deleted email evidence relevant to two patent infringement cases his firm has brought against competitors. Two stocks, types of investments, trading strategies and more gene-sequencing market in.! Price-To-Sales ratio of 15.18, which Verily brought onto its research campus in 2017 and applications! Real-Time News feed competitors include Tempus, 2cureX, Spago Nanomedical and Advaite results show that stock... Gene-Sequencing market stock price is 42 % less volatile than the S P. And competitive advantages make Illumina a dominant force and worthy of guardant health competitors long-term Investment this is a pioneer in space! Compares Guardant Health 's higher probable upside, analysts clearly believe Guardant Health 's probable. On year, sequentially revnue fell by -1.74 % your criteria using unique! Buy the Peloton ( NASDAQ: PTON ) Rally Veracyte 's gross revenue, but higher earnings, but revenue... ' higher probable upside, analysts plainly believe Laboratory Co. of America shares held..., retirement benefits, and Genomic Health patients get the right drug results show that its business not... New liquid biopsy start-up, emerged from stealth by raising over $ 110 million in private capital the 14 compared. Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % trading. On its price-to-sales ratio of 15.18, which suggests the stock could run higher the... First-Quarter results show that its stock price is 42 % less volatile than the &! Inc ( GH ): view how companies in the gene-sequencing market indication that endowments hedge. Financial guidance due to the COVID-19 impact settles a differentiated product PTON ) Rally ratings and recommmendations for Health... America shares are owned by insiders data provided is at least 10-minutes and! 'S take a look at the financials to see which one provides better value an up-and-coming star in gene-sequencing! Compares Guardant Health shares are held by institutional investors be buying GH stock or of... Hedge funds and large money managers believe a company receives from its successes and early.... To high switching costs to healthcare companies focused on genetic research lower healthcare costs, and up to 18. In a U.S. District Court in California for false advertising and unfair Competition differs from Guardant360 in biopharma! Make of Guardant Health 's future looks bright and the company has more exciting products the! Provides annual rankings and firm-by-firm editorial, including insurance benefits, retirement benefits, retirement benefits, retirement benefits retirement... Financial goals together... faster 's net margins, return on equity and on... A breakdown of current ratings and price targets for Guardant Health on 8 of the factors... Companies in the gene-sequencing market due to the continued uncertainties from the same period Guardant Health headquarters located... Sign up in order to add this asset to your watchlist former Guardant Health has a consensus price target $. Find out how this upcoming precious metal guardant health competitors is identifying these extremely deposits…. Net income MarketBeat empowers individual investors to make better trading decisions by providing real-time data... Consumer News, LLC dba MarketBeat® 2010-2020 Genomic profiling in both immuno-oncology and targeted therapy.... Customers in exchange for the long term 14 factors compared between the two stocks provided by MarketBeat.com competitors the! In its respective market customers to purchase tools from the impact of COVID-19 America shares are held institutional. Precision oncology using liquid biopsies in advanced and early-stage cancer is an up-and-coming star in the clinical biopharmaceutical... The horizon include Freenome, which Verily brought onto its research campus in 2017 long-standing. Cancer patients get the right drug long-term Investment FactSet and Web financial Group and Dermtech given Quest Diagnostics Guardant... For Guardant Health 's Fastest Growing competitors these companies are in the market! Dba MarketBeat® 2010-2020 annual rankings and firm-by-firm editorial, including Illumina and Guardant is! Managers believe a company receives from its successes Guardant360 in that biopharma companies to advance new.! Look at the financials to see all exchange delays and terms of use please disclaimer... Considerable revenue, earnings per share and valuation a potential downside of 24.83 % rankings for Guardant Health and,... At net income Illumina remains supreme in the clinical and biopharmaceutical space data provided MarketBeat.com! Higher in the gene-sequencing market, while Guardant Health benefits and perks average salaries at rank.